ArticleMediastinum (Hong Kong, China)2026
Very late recurrence of thymoma after 14 years: an International Thymic Malignancy Interest Group Tumor Board case report from a Turkish multidisciplinary team.
Article in Mediastinum (Hong Kong, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thymomas are generally slow-growing tumors with a favorable prognosis; however, late recurrences have been well documented in the literature and may occur many years after complete (R0) resection. In this report, the multimodal management of a patient who experienced recurrence 14 years after surgery is presented as discussed during the multidisciplinary International Thymic Malignancy Interest Group (ITMIG) Tumor Board meeting on 17 October 2025. Case Description: An 18-year-old female patient underwent median sternotomy in 2006 for resection of a 15.5-cm type B1 thymoma. Histopathological examination revealed microscopic transcapsular invasion with negative surgical margins, and adjuvant therapy was not recommended at that time. In 2020, progressive myasthenic symptoms led to re-evaluation, and imaging demonstrated multifocal right pleural recurrence with suspected involvement of the inferior vena cava and hepatic interface. Fine-needle aspiration biopsy confirmed recurrent World Health Organization (WHO) type B1 thymoma. Because complete resection was considered unlikely, the patient received cisplatin/etoposide chemotherapy followed by definitive chemoradiotherapy, achieving major radiologic response and disease stability. In 2024, after progression of a paravertebral recurrent lesion, salvage surgery was performed via right thoracotomy, including wedge resection, pleurectomy, mediastinal lymph node dissection, and intraoperative hyperthermic intrathoracic chemotherapy. The patient has since remained disease-free on continued surveillance. Conclusions: In thymic epithelial tumors with increased risk of recurrence, multimodal treatment strategies may improve long-term outcomes. This case highlights that very late recurrence may occur even after R0 resection and supports lifelong surveillance. Long-term follow-up should include periodic contrast-enhanced thoracic computed tomography, with magnetic resonance imaging considered in younger patients to reduce cumulative radiation exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.